BWAY trades 74.9% below Wall Street's consensus target of $19.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BWAY achieves its forward estimates and maintains a stable P/E multiple of 36.4x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, BrainsWay Ltd. (BWAY) has a Wall Street consensus price target of $19.50, based on estimates from 8 covering analysts. With the stock currently trading at $11.15, this represents a potential upside of +74.9%. The company has a market capitalization of $437M.
Analyst price targets range from a low of $19.00 to a high of $20.00, representing a 5% spread in expectations. The median target of $19.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BWAY trades at a trailing P/E of 23.4x and forward P/E of 36.4x. Analysts expect EPS to grow -35.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 STIMNeuronetics, Inc. | $150M | $2.15 | $5.00 | +132.6% | Buy | — | 8 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 LIVNLivaNova PLC | $4.9B | $89.99 | $100.00 | +11.1% | Buy | 20.7x | 15 |
 GKOSGlaukos Corporation | $13.2B | $224.41 | $218.70 | -2.5% | Buy | 332.7x | 25 |
 ELMDElectromed, Inc. | $225M | $27.17 | $48.50 | +78.5% | Buy | 22.3x | 5 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 INVAInnoviva, Inc. | $1.4B | $19.10 | $38.00 | +99.0% | Buy | 7.9x | 11 |
 ACMRACM Research, Inc. | $2.9B | $44.61 | $122.75 | +175.2% | Buy | 20.1x | 10 |
Quick answers to the most common questions about buying BWAY stock.
The consensus Wall Street price target for BWAY is $19.5, representing 74.9% upside from the current price of $11.15. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BWAY has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $19.5 implies 74.9% upside from current levels.
At a forward P/E of 36.3547x, BWAY trades at a premium valuation. The consensus price target of $19.5 (74.9% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $20 for BWAY, while the most conservative target is $19. The consensus of $19.5 represents the median expectation. These targets typically reflect 12-month expectations.
BWAY is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BWAY stock forecast based on 8 Wall Street analysts shows a consensus price target of $19.5, with estimates ranging from $19 (bear case) to $20 (bull case). The median consensus rating is "Buy".
BWAY trades at a forward P/E ratio of 36.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 23.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BWAY, with a "Buy" consensus rating and $19.5 price target (74.9% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BWAY analyst price targets range from $19 to $20, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.